Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Neurothera Labs Inc. manages a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The company currently has 2 pending office actions. The management of these 2 pending office actions requires coordination across multiple examiners. These actions are distributed across 2 distinct examiners, indicating a diversified examination process for the pending applications. This distribution of 2 distinct examiners represents a more complex prosecution environment than the 1 pending office action assigned to the busiest examiner.
The prosecution activity is concentrated within 1 distinct art unit. SZNAIDMAN, MARCOS L is identified as the busiest examiner for the portfolio and is responsible for 1 pending office action. This 1 pending office action is currently assigned to the busiest examiner while the remaining workload is handled by another examiner in the same area. For the company, this requires a management strategy to ensure consistency across the 1 distinct art unit despite the involvement of multiple examiners.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SZNAIDMAN, MARCOS L | 1 | 37.3% | +16.2% |
| RODRIGUEZ, RAYNA B | 1 | 33.6% | +19.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18019210 | METHODS FOR MAINTAINING MICROVASCULAR INTEGRITY | SZNAIDMAN, MARCOS L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18019210 | METHODS FOR MAINTAINING MICROVASCULAR INTEGRITY | SZNAIDMAN, MARCOS L | — |
| 17459583 | COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES | RODRIGUEZ, RAYNA B | — |
| Art Unit | Apps |
|---|---|
| 1628 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18019210 | METHODS FOR MAINTAINING MICROVASCULAR INTEGRITY | SZNAIDMAN, MARCOS L | 1628 | §102§103§112 | Non-Final OA | — | Pending | Feb 01, 2023 |
| 17459583 | COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES | RODRIGUEZ, RAYNA B | 1628 | §103 | Final Rejection | — | Pending | Aug 27, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial